VVL prioritises the recognition of α- or β-linked terminal N-acetylgalactosamine, particularly individual α-n-acetylgalactosamine residues linked to serine or threonine in the polypeptide (Tn antigen). There is evidence that such lectins may also require specific amino acid sequences at glycosylated receptor sites. Disaccharide galactose (alpha-1,3) n-acetylgalactosamine is also a potent inhibitor of this lectin.
For research use only, not for clinical use.